摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[1-(3-bromophenyl)-1H-[1,2,3]triazol-4-ylmethyl]diethylamine | 1401774-28-4

中文名称
——
中文别名
——
英文名称
[1-(3-bromophenyl)-1H-[1,2,3]triazol-4-ylmethyl]diethylamine
英文别名
N-((1-(3-bromophenyl)-1H-1,2,3-triazol-4-yl)methyl)-N-ethylethanamine;N-[[1-(3-bromophenyl)triazol-4-yl]methyl]-N-ethylethanamine
[1-(3-bromophenyl)-1H-[1,2,3]triazol-4-ylmethyl]diethylamine化学式
CAS
1401774-28-4
化学式
C13H17BrN4
mdl
——
分子量
309.209
InChiKey
PXSJSOSMJCLQLT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    34
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-(4-aminophenyl)-4-methoxybenzamide[1-(3-bromophenyl)-1H-[1,2,3]triazol-4-ylmethyl]diethylaminetris-(dibenzylideneacetone)dipalladium(0)2-二环己基磷-2,4,6-三异丙基联苯 potassium carbonate 作用下, 以 叔丁醇 为溶剂, 反应 22.0h, 以52%的产率得到N-{4-[3-(4-(diethylaminomethyl)-[1,2,3]triazol-1-yl)phenylamino]phenyl}-4-methoxybenzamide
    参考文献:
    名称:
    Compounds for use as therapeutic agents affecting p53 expression and/or activity
    摘要:
    本发明涉及化合物(I),其中R1和R2分别代表氢原子,(C1-C4)烷氧基,氟代(C1-C4)烷氧基,羟基,苄氧基,二(C1-C4)烷基氨基,吡啶基乙烯基,嘧啶基乙烯基,苯乙烯基,或-NHCO苯基;R3、R4和R5分别代表氢原子,(C1-C4)烷基,CONHR6基团,-CONR7R8基团,-SO2NHR6基团,或杂环烷基,可选择地被卤原子取代,-(CH2)nNR7R8基团或羟基(C1-C4)烷基;R6代表氢原子,-(CHR9)m(CH2)nNR7R8基团或(C1-C6)烷基,可选择地被羟基取代;或其药学上可接受的盐之一,用作预防、抑制或治疗患有该疾病的患者的药剂,所述疾病涉及到p53蛋白的失调。其中一些化合物是新的,也是本发明的一部分。
    公开号:
    EP2505198A1
  • 作为产物:
    描述:
    N,N-二乙氨基炔丙胺甲酸盐1-溴-3-碘苯 在 sodium azide 、 copper(ll) sulfate pentahydratesodium carbonatesodium ascorbate 作用下, 以 二甲基亚砜 为溶剂, 反应 16.0h, 以70%的产率得到[1-(3-bromophenyl)-1H-[1,2,3]triazol-4-ylmethyl]diethylamine
    参考文献:
    名称:
    Compounds for use as therapeutic agents affecting p53 expression and/or activity
    摘要:
    本发明涉及化合物(I),其中R1和R2分别代表氢原子,(C1-C4)烷氧基,氟代(C1-C4)烷氧基,羟基,苄氧基,二(C1-C4)烷基氨基,吡啶基乙烯基,嘧啶基乙烯基,苯乙烯基,或-NHCO苯基;R3、R4和R5分别代表氢原子,(C1-C4)烷基,CONHR6基团,-CONR7R8基团,-SO2NHR6基团,或杂环烷基,可选择地被卤原子取代,-(CH2)nNR7R8基团或羟基(C1-C4)烷基;R6代表氢原子,-(CHR9)m(CH2)nNR7R8基团或(C1-C6)烷基,可选择地被羟基取代;或其药学上可接受的盐之一,用作预防、抑制或治疗患有该疾病的患者的药剂,所述疾病涉及到p53蛋白的失调。其中一些化合物是新的,也是本发明的一部分。
    公开号:
    EP2505198A1
点击查看最新优质反应信息

文献信息

  • COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY
    申请人:Scherrer Didier
    公开号:US20140206690A1
    公开(公告)日:2014-07-24
    The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C 1 -C 4 )alkoxy group, a fluoro(C 1 -C 4 )alkoxy group, a hydroxyl group, a benzyloxy group, a di(C 1 -C 4 )alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C 1 -C 4 )alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO 2 NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH 2 ) n NR7R8 group or a hydroxy(C 1 -C 4 )alkyl group; R6 represents a hydrogen atom, a —(CHR9) m (CH 2 ) n NR7R8 group or a (C 1- C 6 )alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.
    本发明涉及化合物(I),其中R1和R2分别表示氢原子,(C1-C4)烷氧基,(C1-C4)烷氧基,羟基,苄氧基,二(C1-C4)烷基基,吡啶乙烯基嘧啶乙烯基苯乙烯基或—NHCO苯基;R3,R4和R5分别表示氢原子,(C1-C4)烷基,CONHR6基,—CONR7R8基,—SO2NHR6基或杂环基,所述杂环基可选地被卤原子,—(CH2)nNR7R8基或羟基(C1-C4)烷基取代;R6表示氢原子,—(CHR9)m( )nNR7R8基或(C1-C6)烷基,可选地被羟基取代;或其药学上可接受的盐之一,用于预防,抑制或治疗患有p53失调的患者的疾病的方法。其中一些化合物是新的,也是本发明的一部分。
  • Compounds for use as therapeutic agents affecting P53 expression and/or activity
    申请人:ABIVAX
    公开号:US10538485B2
    公开(公告)日:2020-01-21
    The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.
    本公开涉及化合物 (I) 其中 R1 和 R2 独立地代表氢原子、(C1-C4)烷氧基、(C1-C4)烷氧基、羟基、苄氧基、二(C1-C4)烷基基、吡啶乙烯基嘧啶乙烯基苯乙烯基或 -NHCOphenyl 基;R3、R4 和 R5 各自代表氢原子、(C1-C4)烷基、CONHR6 基团、-CONR7R8 基团、-SO2NHR6 基团或任选被卤素原子、-(CH2)nNR7R8 基团或羟基(C1-C4)烷基取代的杂芳基;R6代表氢原子、-(CHR9)m( )nNR7R8基团或任选被羟基取代的(C1-C6)烷基;或其任何药学上可接受的盐,用于预防、抑制或治疗患者的疾病,所述疾病涉及p53失调。其中一些化合物是新化合物,也是本公开的一部分。
  • US9890112B2
    申请人:——
    公开号:US9890112B2
    公开(公告)日:2018-02-13
  • [EN] COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY<br/>[FR] COMPOSÉS POUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES AFFECTANT L'EXPRESSION ET/OU L'ACTIVITÉ DE P53
    申请人:SPLICOS SOC
    公开号:WO2012131656A2
    公开(公告)日:2012-10-04
    The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl- vinyl group, a pyrimidinyl- vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.
查看更多